mRNA vaccine for relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests an experimental mRNA therapy called mRNA-2808 for people with multiple myeloma that has returned or stopped responding to prior treatments. It aims to see if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that came back or didn't respond to earlier treatments.
- You've already tried a proteasome inhibitor, an immunomodulatory drug (IMiD), and a CD38-targeted antibody therapy.
- Your disease is measurable, meaning you have enough of certain markers (M-protein, urine M-protein, free light chains, a plasmacytoma, or high bone marrow plasma cells).
- You have not had certain treatments recently, like certain chemotherapies, radiation, antibody therapies, or cell transplants (within specified timeframes).
- You do not have multiple myeloma in your brain or spinal cord, active plasma cell leukemia, or other specific health issues that would exclude you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MBS314 for people whose multiple myeloma has returned or stopped responding to other treatments. The goal is to see if MBS314 can help shrink or control the myeloma.
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This trial tests a new injected drug for people with multiple myeloma that has returned or stopped responding to at least 3 prior treatments. The goal is to see if the drug is safe and works against the cancer.
This study tests an experimental drug called RN9101 for people with multiple myeloma that has returned or stopped responding to other treatments. The drug targets a protein called BCMA found on myeloma cells, and the goal is to see if it is safe and can help control the disease.
This Phase 1 trial tests a new drug called RO7851624 in patients whose multiple myeloma has come back or stopped responding to prior treatments. The goal is to understand how safe and effective this drug is.
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.